Circio to present comprehensive circVec-AAV in vivo data package at ESGCT 2025

Summary by AI BETAClose X

Circio Holding ASA will present its circVec expression platform at the European Society of Gene and Cell Therapy annual meeting in Seville, Spain, from October 7-10, 2025. The presentation, poster no. 1041, will highlight the advantages of circVec-AAV in vivo over conventional AAVs in heart and other tissues. Recent in vivo results demonstrate circVec's potential as a novel expression system, showing statistically significant increases in expression in multiple tissues for several circVec-AAV variants. The circVec platform has demonstrated up to 40-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems and a 75-fold increased RNA half-life.

Disclaimer*

UK 100

Latest directors dealings